Non-inferiority testing for risk ratio, odds ratio and number needed to treat in three-arm trial

被引:9
作者
Chowdhury, Shrabanti [2 ]
Tiwari, Ram C. [3 ]
Ghosh, Samiran [1 ,2 ]
机构
[1] Dept Family Med & Publ Hlth Sci, Detroit, MI USA
[2] Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48202 USA
[3] US FDA, Div Biostat, CDRH, Rockville, MD 20857 USA
关键词
Assay sensitivity; Binary outcome; Fraction margin; Non-inferiority margin; Odds/risk ratio/NNT; Three-arm trial; BAYESIAN-APPROACH; NONINFERIORITY TRIALS; DESIGN; MARGIN;
D O I
10.1016/j.csda.2018.08.018
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Three-arm non-inferiority (NI) trial including the experimental treatment, an active reference treatment, and a placebo where the outcome of interest is binary are considered. While the risk difference (RD) is the most common and well explored functional form for testing efficacy (or effectiveness), however, recent FDA guideline suggested measures such as relative risk (RR), odds ratio (OR), number needed to treat (NNT) among others, on the basis of which NI can be claimed for binary outcome. Albeit, developing test based on these different functions of binary outcome are challenging. This is because the construction and interpretation of NI margin for such functions are non-trivial extensions of RD based approach. A Frequentist test based on traditional fraction margin approach for RR, OR and NNT are proposed first. Furthermore a conditional testing approach is developed by incorporating assay sensitivity (AS) condition directly into NI testing. A detailed discussion of sample size/power calculation are also put forward which could be readily used while designing such trials in practice. A clinical trial data is reanalyzed to demonstrate the presented approach. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:70 / 83
页数:14
相关论文
共 37 条
[1]   Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review [J].
Althunian, Turki A. ;
de Boer, Anthonius ;
Klungel, Olaf H. ;
Insani, Widya N. ;
Groenwold, Rolf H. H. .
TRIALS, 2017, 18
[2]  
[Anonymous], 2005, GUID CHOIC NON MARG
[3]  
[Anonymous], 2013, INNOVATIONS CLIN SA
[4]  
[Anonymous], 2009, INT C HARM TECHN REQ
[5]   An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees [J].
Brown, David ;
Volkers, Peter ;
Day, Simon .
STATISTICS IN MEDICINE, 2006, 25 (10) :1623-1627
[6]   Challenge of multiple co-primary endpoints: A new approach [J].
Chuang-Stein, Christy ;
Stryszak, Paul ;
Dmitrienko, Alex ;
Offen, Walter .
STATISTICS IN MEDICINE, 2007, 26 (06) :1181-1192
[7]   THE NUMBER NEEDED TO TREAT - A CLINICALLY USEFUL MEASURE OF TREATMENT EFFECT [J].
COOK, RJ ;
SACKETT, DL .
BRITISH MEDICAL JOURNAL, 1995, 310 (6977) :452-454
[8]   Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics [J].
D'Agostino, RB ;
Massaro, JM ;
Sullivan, LM .
STATISTICS IN MEDICINE, 2003, 22 (02) :169-186
[9]  
Dmitrienko A, 2009, Multiple Testing Problems in Pharmaceutical Statistics
[10]  
FDA, 2016, NON CLIN TRIALS EST